Our study indicates that TLR9 is associated with the mechanism of protection of intranasal LaAg vaccine and suggests that the use of a TLR9 agonist could be considered an adjuvant by intranasal route against leishmaniasis. Here, TLR9 is linked to leishmaniasis.